I-Mab signs first two deals of immuno-oncology discovery initiative

March 10, 2021 11:29 PM UTC

I-Mab’s deals with Complix and Shanghai Affinity mark the start of a new discovery initiative to build out the Chinese biotech’s immuno-oncology pipeline. 

I-Mab Biopharma (NASDAQ:IMAB) said Wednesday it partnered with Belgian biotech Complix N.V. to discover and develop cell-penetrating Alphabodies, a peptide format therapeutic, against two undisclosed, intracellular immuno-oncology targets. I-Mab will have exclusive rights in Greater China, while the partners will share development and commercialization rights outside of China. ...